Search
Descriptor English: PCSK9 Inhibitors
Descriptor Spanish: Inhibidores de PCSK9
Descriptor inhibidores de PCSK9
Entry term(s) inhibidores de la PCSK9 cardiovasculares
Scope note: Agentes que inhiben la proproteína convertasa subtilisina/kexina de tipo 9 (véase PROPROTEÍNA CONVERTASA 9 [PCSK9]), una enzima que desempeña un papel importante en la degradación de los receptores de las LDL. Favorece el catabolismo de las LDL y reduce el nivel plasmático de colesterol LDL (C-LDL).
Descriptor Portuguese: Inibidores de PCSK9
Descriptor French: Inhibiteurs de PCSK9
Entry term(s): Cardiovascular PCSK9 Inhibitors
Cardiovascular, PCSK9 Inhibitors
Inhibitors, Cardiovascular PCSK9
PCSK9 Inhibitors Cardiovascular
PCSK9 Inhibitors, Cardiovascular
Tree number(s): D27.505.519.186.071.202.685
D27.505.519.389.745.800.506
D27.505.954.557.500.202.685
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000091362
Scope note: Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Entry Combination: antagonists & inhibitors:Proprotein Convertase 9
Previous Indexing: Anticholesteremic Agents (2018-2021)
Public MeSH Note: 2022
History Note: 2022
DeCS ID: 59868
Unique ID: D000091362
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2022/01/01
Date of Entry: 2021/07/09
Revision Date: 2021/07/08
PCSK9 Inhibitors - Preferred
Concept UI M000748765
Scope note Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level.
Preferred term PCSK9 Inhibitors
PCSK9 Inhibitors, Cardiovascular - Narrower
Concept UI M000748766
Preferred term PCSK9 Inhibitors, Cardiovascular
Entry term(s) Cardiovascular PCSK9 Inhibitors
Cardiovascular, PCSK9 Inhibitors
Inhibitors, Cardiovascular PCSK9
PCSK9 Inhibitors Cardiovascular



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey